Literature DB >> 8302580

p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation.

M Volkmann1, W J Hofmann, M Müller, U Räth, G Otto, H Zentgraf, P R Galle.   

Abstract

Mutations in the p53 tumour suppressor gene have been recently described in hepatocellular carcinomas (HCC) from high risk areas such as China and South Africa. Our study was designed to assess the importance of p53 aberrations in HCCs from Europe, where the major risk factors in hepatocarcinogenesis, aflatoxin exposure and chronic hepatitis B virus (HBV) infection, do not play a dominant role. We investigated 22 HCCs and, as controls, their corresponding tumour-free liver tissues, seven livers with primary biliary cirrhosis and four morphologically normal livers. p53 overexpression, which is usually associated with point mutations of the p53 gene, was detected in 10 of the 22 HCCs by immunoblotting and immunohistochemistry. p53 expression was restricted to the nucleus in the positive cells, while all cells in the control tissues were negative. There was no obvious etiological preference in the p53 positive tumours. Particularly, underlying chronic HBV infection did not appear to be associated with an increased rate of p53 overexpression in European HCCs. SSCP and sequence analysis of exons 5-8 of the p53 gene revealed point mutations in six out of eight tumours with increased steady state levels of p53. In conclusion, our study demonstrates increased p53 levels due to point mutations in a significant proportion of European HCCs. The codon 249 mutation, which was detected in one of the cases, is not predominant in these tumours.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302580

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  17 in total

1.  Assessment of the Proliferative Marker Ki-67 and p53 Protein Expression in HBV- and HCV-related Hepatocellular Carcinoma Cases in Egypt.

Authors:  Waleed S Mohamed; Masoud M Omar; Tarek M Khayri; Ibrahim M Fakhr
Journal:  Int J Health Sci (Qassim)       Date:  2008-01

Review 2.  Hepatic neoplasia: reflections and ruminations.

Authors:  K Aterman
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Classification of hepatocellular carcinoma according to hepatocellular and biliary differentiation markers. Clinical and biological implications.

Authors:  P C Wu; J W Fang; V K Lau; C L Lai; C K Lo; J Y Lau
Journal:  Am J Pathol       Date:  1996-10       Impact factor: 4.307

4.  Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes.

Authors:  Perumal Vivekanandan; Michael Torbenson; Banumathi Ramakrishna
Journal:  J Gastrointest Cancer       Date:  2011-03

5.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53.

Authors:  M Müller; S Strand; H Hug; E M Heinemann; H Walczak; W J Hofmann; W Stremmel; P H Krammer; P R Galle
Journal:  J Clin Invest       Date:  1997-02-01       Impact factor: 14.808

6.  Alpha-fetoprotein and p53 autoantibodies in patients with chronic hepatitis C.

Authors:  J Raedle; W K Roth; G Oremek; W F Caspary; S Zeuzem
Journal:  Dig Dis Sci       Date:  1995-12       Impact factor: 3.199

Review 7.  Having it both ways: transcription factors that bind DNA and RNA.

Authors:  Laura A Cassiday; L James Maher
Journal:  Nucleic Acids Res       Date:  2002-10-01       Impact factor: 16.971

8.  Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells.

Authors:  Nuri Ozturk; Esra Erdal; Mine Mumcuoglu; Kamil C Akcali; Ozden Yalcin; Serif Senturk; Ayca Arslan-Ergul; Bala Gur; Isik Yulug; Rengul Cetin-Atalay; Cengiz Yakicier; Tamer Yagci; Mesut Tez; Mehmet Ozturk
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-06       Impact factor: 11.205

9.  Potential role of p53 mutation in chemical hepatocarcinogenesis of rats.

Authors:  Wei-Guo Deng; Yan Fu; Yu-Lin Li; Toshihiro Sugiyama
Journal:  World J Gastroenterol       Date:  2004-01       Impact factor: 5.742

10.  249 TP53 mutation has high prevalence and is correlated with larger and poorly differentiated HCC in Brazilian patients.

Authors:  Jeronimo A Nogueira; Suzane K Ono-Nita; Marcelo E Nita; Marcelo M T de Souza; Eliane P do Carmo; Evandro S Mello; Cristovan Scapulatempo; Denise C Paranaguá-Vezozzo; Flair J Carrilho; Venancio A F Alves
Journal:  BMC Cancer       Date:  2009-06-26       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.